These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30605510)

  • 1. Role of medical reaction in management of inappropriate ventricular arrhythmia diagnosis: the inappropriate Therapy and HOme monitoRiNg (THORN) registry.
    Perrin T; Boveda S; Defaye P; Rosier A; Sadoul N; Bordachar P; Klug D; Ritter P; Belhameche M; Babuty D; Mansourati J; Lazarus A; Deharo JC
    Europace; 2019 Apr; 21(4):607-615. PubMed ID: 30605510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of subcutaneous implantable cardioverter-defibrillators and determinants of inappropriate shock delivery.
    Mesquita J; Cavaco D; Ferreira A; Lopes N; Santos PG; Carvalho MS; Haas A; Costa F; Carmo P; Morgado F; Adragão P; Mendes M
    Int J Cardiol; 2017 Apr; 232():176-180. PubMed ID: 28082086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
    Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
    Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reprogramming the tachycardia parameters with long-detection strategy in patients with pre-existing implantable cardioverter-defibrillator.
    Bozyel S; Aktas M; Mutluer FO; Guler TE; Dervis E; Argan O; Celikyurt U; Agir A; Vural A
    Acta Cardiol; 2019 Jun; 74(3):246-251. PubMed ID: 30058473
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients.
    Zhou Y; Zhao S; Chen K; Hua W; Su Y; Chen S; Liang Z; Xu W; Zhang S
    BMC Cardiovasc Disord; 2019 Oct; 19(1):230. PubMed ID: 31638918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long Detection Programming in Single-Chamber Defibrillators Reduces Unnecessary Therapies and Mortality: The ADVANCE III Trial.
    Gasparini M; Lunati MG; Proclemer A; Arenal A; Kloppe A; Martínez Ferrer JB; Hersi AS; Gulaj M; Wijffels MCE; Santi E; Manotta L; Varma N
    JACC Clin Electrophysiol; 2017 Nov; 3(11):1275-1282. PubMed ID: 29759624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication.
    Schaer B; Kühne M; Reichlin T; Osswald S; Sticherling C
    Europace; 2016 Feb; 18(2):227-31. PubMed ID: 26063686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic Review and Meta-Analysis of Clinical Outcome After Implantable Cardioverter-Defibrillator Therapy in Patients With Chagas Heart Disease.
    Rassi FM; Minohara L; Rassi A; Correia LCL; Marin-Neto JA; Rassi A; da Silva Menezes A
    JACC Clin Electrophysiol; 2019 Oct; 5(10):1213-1223. PubMed ID: 31648747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial.
    Kloppe A; Proclemer A; Arenal A; Lunati M; Martìnez Ferrer JB; Hersi A; Gulaj M; Wijffels MC; Santi E; Manotta L; Mangoni L; Gasparini M
    Circulation; 2014 Jul; 130(4):308-14. PubMed ID: 24838360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
    Weissler-Snir A; Dorian P; Rakowski H; Care M; Spears D
    Heart Rhythm; 2021 Jan; 18(1):63-70. PubMed ID: 32800967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants.
    Rowin EJ; Burrows A; Madias C; Estes NAM; Link MS; Maron MS; Maron BJ
    Circ Arrhythm Electrophysiol; 2020 Oct; 13(10):e008123. PubMed ID: 32897759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inappropriate cardioverter-defibrillator discharge continues to be a major problem in clinical practice.
    Jodko Ł; Kornacewicz-Jach Z; Kaźmierczak J; Rzeuski R; Zielonka J; Kaliszczak R; Safranow K
    Cardiol J; 2009; 16(5):432-9. PubMed ID: 19753522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SVT discrimination algorithms significantly reduce the rate of inappropriate therapy in the setting of modern-day delayed high-rate detection programming.
    Cheng A; Auricchio A; Schloss EJ; Kurita T; Sterns LD; Gerritse B; Brown ML; Fagan DH; Lexcen DR; Ellenbogen KA
    J Cardiovasc Electrophysiol; 2019 Dec; 30(12):2877-2884. PubMed ID: 31646695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of implantable cardioverter-defibrillator implantation in secondary prevention of sudden cardiac death.
    Boulé S; Sémichon M; Guédon-Moreau L; Drumez É; Kouakam C; Marquié C; Brigadeau F; Kacet S; Potelle C; Escande W; Souissi Z; Lacroix D; Duhamel A; Klug D
    Arch Cardiovasc Dis; 2016 Oct; 109(10):517-526. PubMed ID: 27342808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Prevalence of Inappropriate Shocks in Patients With Inherited Arrhythmia Syndromes With the Subcutaneous Implantable Defibrillator Single Center Experience and Long-Term Follow-Up.
    Rudic B; Tülümen E; Berlin V; Röger S; Stach K; Liebe V; El-Battrawy I; Dösch C; Papavassiliu T; Akin I; Borggrefe M; Kuschyk J
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29042423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.
    Kron J; Sauer W; Schuller J; Bogun F; Crawford T; Sarsam S; Rosenfeld L; Mitiku TY; Cooper JM; Mehta D; Greenspon AJ; Ortman M; Delurgio DB; Valadri R; Narasimhan C; Swapna N; Singh JP; Danik S; Markowitz SM; Almquist AK; Krahn AD; Wolfe LG; Feinstein S; Ellenbogen KA
    Europace; 2013 Mar; 15(3):347-54. PubMed ID: 23002195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systolic Blood Pressure and Risk for Ventricular Arrhythmia in Patients With an Implantable Cardioverter Defibrillator.
    Beinart R; Goldenberg I; Younis A; McNitt S; Huang D; Aktas MK; Spencer R; Kutyifa V; Nof E
    Am J Cardiol; 2021 Mar; 143():74-79. PubMed ID: 33359194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.
    Hodgkinson KA; Howes AJ; Boland P; Shen XS; Stuckless S; Young TL; Curtis F; Collier A; Parfrey PS; Connors SP
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):. PubMed ID: 26966288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of inappropriate ICD therapies in patients with primary prevention of sudden cardiac death: DECREASE study.
    Schwab JO; Bonnemeier H; Kleemann T; Brachmann J; Fischer S; Birkenhauer F; Eberhardt F
    Clin Res Cardiol; 2015 Dec; 104(12):1021-32. PubMed ID: 26002818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.